19/05/2022at 09:10

Novo Holdings establishes new firm managed by biotech veterans

Co-Founder and former CSO of Orphazyme Thomas Kirkegaard Jensen and Bo Rode Hansen, CEO of Scandion Oncology, are both involved in another secret venture backed by Novo Holdings.

by christopher due karlsson, translated by daniel pedersen

Novo Holdings, the holdings company which owns Novo Nordisk, has founded a Danish private limited company named Aloop Therapeutics, with Orphazyme co-founder Thomas Kirkegaard Jensen as a director and Sandion Oncology CEO Bo Rode Hansen as chair of the board, according to a filing on the Danish Central Business Register (CVR).

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

Access all locked articles
Receive our daily newsletters
Access our app

Get full access for you and your coworkers

Start a free company trial today

Novo Holdings silent on newly created company with million-dollar backing
For subscribers
Novo Holdings eyes opportunities as biotech bubble bursts
For subscribers
Danish life science foundations broke investment records in 2021
For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Front page now

Hearing health

William Demant Invest report reveals GN Group stake

The investment firm’s ownership share in GN Group was enough to foil plans to raise DKK 7bn.

For subscribers

Pharma & biotech

Adolescent patients' eczema improved in Leo Pharma's late-stage testing

For subscribers

Hearing health

DNB surprised by GN's lack of backup plan

For subscribers

Pharma & biotech

Leo Pharma presents positive data in hand eczema phase III trial

For subscribers

Foto: Guillaume Souvant/Reuters/Ritzau Scanpix

Pharma & biotech

Six-month Ozempic shortage mostly over after weight-loss craze drained supply

For subscribers

Foto: Tingshu Wang/Reuters/Ritzau Scanpix

Regulation

Competition sharpens on active ingredient production – EU weighs measures

For subscribers

Novo Nordisk reacts to suspension: "We take the decision very seriously"

Novo Nordisk, which has been ousted from UK pharma group ABPI for two years, does not want to comment further on its punishment for misleading marketing.

For subscribers

Hearing health

DNB surprised by GN's lack of backup plan

The lack of support for GN’s scrapped capital raise was to be anticipated, says a DNB analyst, meaning it would have made sense to make a plan B in advance.

For subscribers

Foto: Jacob Gronholt-Pedersen/Reuters/Ritzau Scanpix

Pharma & biotech

UK pharma group suspends Novo Nordisk for two years

Novo Nordisk has been suspended due to misleading marketing that breached the Code of Practice of the Association of the British Pharmaceutical Industry.

For subscribers